1. Home
  2. LDWY vs NCNA Comparison

LDWY vs NCNA Comparison

Compare LDWY & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LDWY
  • NCNA
  • Stock Information
  • Founded
  • LDWY 1990
  • NCNA 1997
  • Country
  • LDWY United States
  • NCNA United Kingdom
  • Employees
  • LDWY N/A
  • NCNA N/A
  • Industry
  • LDWY Advertising
  • NCNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • LDWY Consumer Discretionary
  • NCNA Health Care
  • Exchange
  • LDWY Nasdaq
  • NCNA Nasdaq
  • Market Cap
  • LDWY 7.2M
  • NCNA 7.6M
  • IPO Year
  • LDWY 1991
  • NCNA 2017
  • Fundamental
  • Price
  • LDWY $3.88
  • NCNA $3.41
  • Analyst Decision
  • LDWY
  • NCNA
  • Analyst Count
  • LDWY 0
  • NCNA 0
  • Target Price
  • LDWY N/A
  • NCNA N/A
  • AVG Volume (30 Days)
  • LDWY 20.0K
  • NCNA 205.1K
  • Earning Date
  • LDWY 11-10-2025
  • NCNA 11-13-2025
  • Dividend Yield
  • LDWY N/A
  • NCNA N/A
  • EPS Growth
  • LDWY N/A
  • NCNA N/A
  • EPS
  • LDWY 0.70
  • NCNA N/A
  • Revenue
  • LDWY $69,769,000.00
  • NCNA N/A
  • Revenue This Year
  • LDWY N/A
  • NCNA N/A
  • Revenue Next Year
  • LDWY N/A
  • NCNA N/A
  • P/E Ratio
  • LDWY $5.26
  • NCNA N/A
  • Revenue Growth
  • LDWY 121.91
  • NCNA N/A
  • 52 Week Low
  • LDWY $3.43
  • NCNA $2.78
  • 52 Week High
  • LDWY $6.19
  • NCNA $330.00
  • Technical
  • Relative Strength Index (RSI)
  • LDWY 39.52
  • NCNA 38.82
  • Support Level
  • LDWY $3.54
  • NCNA $3.55
  • Resistance Level
  • LDWY $4.10
  • NCNA $3.86
  • Average True Range (ATR)
  • LDWY 0.45
  • NCNA 0.28
  • MACD
  • LDWY -0.05
  • NCNA -0.05
  • Stochastic Oscillator
  • LDWY 8.04
  • NCNA 16.67

About LDWY Lendway Inc. (DE)

Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Share on Social Networks: